Boston Scientific Microwave BPH Pact Follows Tech Investment Strategy
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's equity investment in microwave benign prostatic hyperplasia (BPH) therapy developer Celsion, including worldwide distribution rights, could lead to an outright purchase of the technology
You may also be interested in...
Boston Scientific To Market Celsion’s Prolieve BPH Device Immediately
Boston Scientific will promote Celsion's Prolieve microwave urethroplasty system as a less-painful alternative to existing treatments for benign prostatic hyperplasia (BPH), following FDA approval Feb. 19
Boston Scientific To Market Celsion’s Prolieve BPH Device Immediately
Boston Scientific will promote Celsion's Prolieve microwave urethroplasty system as a less-painful alternative to existing treatments for benign prostatic hyperplasia (BPH), following FDA approval Feb. 19
Financings In Brief
NitroMed stent investment: Boston Scientific extends R&D collaboration with pharmaceutical firm through 2005 to develop nitric oxide elution compounds that can be used on vascular stents to "complement" Taxus line. The agreement, which expands the firms' original 2001 deal, consists of a $3 mil. up-front payment, adding to the $4 mil. equity investment and $1.5 mil. R&D payments already made by Boston Scientific. NitroMed also will receive milestone payments for development and commercialization targets, as well as royalties if a product is brought to market. Over the past year, Boston Scientific also has invested in Rubicon Medical, 3F Therapeutics and Innovia...